ZLAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Zai Lab Ltd (ZLAB) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. While the company shows some positive revenue growth and promising pipeline developments, the recent insider selling, declining analyst price targets, and lack of strong trading signals suggest a cautious approach is warranted.
The MACD is positive but contracting, RSI is neutral at 59.059, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 18.754), but there is no strong bullish signal.
Q4 2025 revenue increased by 17% YoY, driven by product performance.
Promising clinical trial results for Zoci with an 80% response rate in untreated brain metastases patients.
Management's focus on leveraging a strong pipeline for long-term growth.
Insider selling has increased significantly by 2820.31% over the last month.
Analysts have lowered price targets multiple times recently, reflecting cautious sentiment.
EPS estimates have seen more downward revisions than upward ones, and revenue estimates have been revised downward five times in the last three months.
In Q4 2025, revenue increased by 17% YoY to $127.6 million. However, the company reported a net operating loss of $229.4 million, despite a 19% improvement. R&D and SG&A expenses decreased, but gross margin and EPS have declined YoY.
Analysts maintain a Buy rating, but price targets have been consistently lowered over the past two months, with the latest target at $47 from Citi, down from $53.
